BPB
ABBV icon

Badgley, Phelps & Bell’s AbbVie ABBV Stock Holding History

Badgley, Phelps & Bell’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$1.51M Buy
13,397
+63
+0.5% +$7.09K 0.06% 123
2021
Q1 		$1.44M Buy
13,334
+231
+2% +$24.7K 0.06% 121
2020
Q4 		$1.4M Sell
13,103
-2,498
-16% -$240K 0.06% 117
2020
Q3 		$1.37M Buy
15,601
+936
+6% +$88.1K 0.07% 112
2020
Q2 		$1.44M Buy
14,665
+230
+2% +$20.3K 0.08% 109
2020
Q1 		$1.1M Sell
14,435
-1,101
-7% -$93.8K 0.07% 106
2019
Q4 		$1.38M Buy
15,536
+1,056
+7% +$87.7K 0.07% 114
2019
Q3 		$1.1M Sell
14,480
-2,730
-16% -$187K 0.06% 115
2019
Q2 		$1.25M Sell
17,210
-511
-3% -$40.2K 0.07% 116
2019
Q1 		$1.43M Sell
17,721
-3,384
-16% -$277K 0.09% 115
2018
Q4 		$1.95M Buy
21,105
+140
+0.7% +$12.3K 0.14% 109
2018
Q3 		$1.98M Buy
20,965
+175
+0.8% +$16.6K 0.12% 112
2018
Q2 		$1.93M Sell
20,790
-92
-0.4% -$8.98K 0.13% 110
2018
Q1 		$1.98M Sell
20,882
-402
-2% -$44.2K 0.13% 106
2017
Q4 		$2.06M Buy
21,284
+17,675
+490% +$1.67M 0.14% 105
2017
Q3 		$321K Sell
3,609
-33
-0.9% -$2.51K 0.02% 137
2017
Q2 		$264K Buy
3,642
+392
+12% +$26.4K 0.02% 143
2017
Q1 		$212K Buy
3,250
+23
+0.7% +$1.45K 0.02% 144
2016
Q4 		$202K Sell
3,227
-453
-12% -$27.7K 0.02% 147
2016
Q3 		$232K Buy
3,680
+118
+3% +$7.64K 0.02% 136
2016
Q2 		$221K Buy
3,562
+51
+1% +$3.11K 0.02% 141
2016
Q1 		$201K Sell
3,511
-200
-5% -$11.1K 0.02% 147
2015
Q4 		$220K Buy
+3,711
New +$214K 0.02% 135
2015
Q3 		– Sell
-3,136
Closed -$211K – 171
2015
Q2 		$211K Buy
+3,136
New +$205K 0.02% 126
2015
Q1 		– Sell
-3,686
Closed -$241K – 167
2014
Q4 		$241K Sell
3,686
-194
-5% -$12.2K 0.02% 129
2014
Q3 		$224K Buy
+3,880
New +$215K 0.02% 129
2014
Q1 		– Sell
-4,286
Closed -$226K – 168
2013
Q4 		$226K Buy
+4,286
New +$211K 0.02% 126

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Badgley, Phelps & Bell's ABBV Position: Q2 2021 in Review

Badgley, Phelps & Bell increased its AbbVie (ABBV) stake by 0.47% in Q2 2021, buying an estimated $7.09K and bringing the position to 13,397 shares worth $1.51M. The position accounts for 0.06% of the portfolio, ranked #123.

Badgley, Phelps & Bell first reported a position in ABBV in Q4 2013 and has held it in 27 quarters since. The position peaked at $2.06M in Q4 2017. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

  • Badgley, Phelps & Bell held 13,397 shares of AbbVie worth $1.51M as of Q2 2021.
  • Badgley, Phelps & Bell bought 63 AbbVie shares in Q2 2021, an estimated $7.09K.
  • AbbVie made up 0.06% of Badgley, Phelps & Bell's portfolio in Q2 2021, its #123 holding.
  • Badgley, Phelps & Bell first reported a position in AbbVie in Q4 2013 and has held it in 27 quarters since.
  • Badgley, Phelps & Bell's AbbVie position peaked at $2.06M in Q4 2017.
  • 2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on Badgley, Phelps & Bell's 13F filing for Q2 2021, filed 28 Jul 2021.